Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aardvark Therapeutics, Inc. - Common Stock (NQ:AARD)

1.250 +0.050 (+4.17%)
Delayed Quote Updated: 11:48 AM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 72,141
Open 1.230
Bid (Size) 1.220 (1,000)
Ask (Size) 1.250 (400)
Prev. Close 1.200
Today's Range 1.220 - 1.290
52wk Range 0.9300 - 16.60
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Erasca, Inc. (NASDAQ: ERAS); Planet Fitness, Inc. (NYSE: PLNT); and PROCEPT BioRobotics Corporation (NASDAQ: PRCT): Grabar Law Office is Investigating Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire
News headline image
Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Erasca, Inc. (NASDAQ: ERAS); Insulet Corporation (NASDAQ: PODD); and Planet Fitness, Inc. (NYSE: PLNT): Grabar Law Office is Investigating Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire

Performance

52-Week Range 92.5% below 52-week high
1.250
0.9352W Low 16.6052W High
1 Week 21.4% below 1-week high
1.091W Low 1.591W High

Aardvark Therapeutics, Inc. - Common Stock (AARD) traded between $0.93 and $16.60 over the past 52 weeks and last traded at $1.25, 92.5% below its 52-week high. Over the past week it ranged between $1.09 and $1.59.

Past 12 Months
-3.8%
-76.1%
-82.3%
-76.3%
-90.5%
-88.0%
1W -$0.05
1M -$3.97
3M -$5.83
6M -$4.02
YTD -$11.94
1Y -$9.14

AARD was -88.0% over the past year, -76.3% over six months, -90.5% year to date, -3.8% in the last week.

12 Months vs Market
AARD
-88.0%
DIA
+9.2%
SPY
+10.4%
QQQ
+8.4%
IWM
+14.4%

Over the past 12 months AARD returned -88.0% versus DIA (Dow) +9.2%, SPY (S&P 500) +10.4%, QQQ (Nasdaq 100) +8.4% and IWM (Russell 2000) +14.4%.

Volume & Liquidity 0.12× 3-mo avg
Today 72,141 3-mo avg 587.0K
1W
1.6M
1M
1.6M
3M
587.0K
6M
432.7K
YTD
362.5K
1Y
338.0K

AARD most recently traded 72,141 shares against a 3-month average daily volume of 587.0K.

More News

Read More
Nasdaq Unusual Volume Movers for October 28, 2026 ↗
Via Chartmill
Unusual Volume Stocks: POM, SHFS and BRAI Among Session Movers ↗
Via Chartmill
Unusual Volume in Small-Cap US Stocks: Mixed Session of Gains and Sharp Losses ↗
Via Chartmill
News headline image
Important Notice Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Erasca, Inc. (NASDAQ: ERAS); Power Solutions International, Inc. (NASDAQ: PSIX); and The Simply Good Foods Company (NASDAQ: SMPL): Grabar Law Office is Investigating
From Grabar Law Office
Via GlobeNewswire
After-Hours Movers: Oct. 23 Postmarket Gainers and Losers ↗
Via Chartmill
Top US Stock Gainers and Losers in Today's Session ↗
Via Chartmill
Today's U.S. Session Top Movers: Small-Cap Gainers and Losers ↗
Via Chartmill
Gap-Up and Gap-Down Stocks: October 23, 2026 Session ↗
Via Chartmill
News headline image
Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
Postmarket Movers: After-Hours Gainers and Decliners ↗
Via Chartmill
News headline image
Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Erasca, Inc. (NASDAQ: ERAS); GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI); and New Era Energy & Digital, Inc. (NASDAQ: NUAI): Grabar Law Office is Investigating Claims on
From Grabar Law Office
Via GlobeNewswire
News headline image
Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Bank of America Corporation (NYSE: BAC); Coastal Financial Corporation (NASDAQ: CCB); and Erasca, Inc. (NASDAQ: ERAS): Grabar Law Office is Investigating Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire
News headline image
Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Hub Group, Inc. (NASDAQ: HUBG); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims
From Grabar Law Office
Via GlobeNewswire
News headline image
Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on
From Grabar Law Office
Via GlobeNewswire
News headline image
Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and The Simply Good Foods Company (NASDAQ: SMPL): Grabar Law Office is
From Grabar Law Office
Via GlobeNewswire
News headline image
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors – AARD
From Pomerantz LLP
Via GlobeNewswire
News headline image
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 13, 2026 in Aardvark Therapeutics, Inc. Lawsuit - AARD
From SueWallSt
Via GlobeNewswire
News headline image
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
Levi & Korsinsky Reminds Aardvark Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 13, 2026 - AARD
From Levi & Korsinsky, LLP
Via GlobeNewswire
News headline image
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Duolingo, Inc. (NASDAQ: DUOL); and Ensign Group, Inc. (NASDAQ: ENSG): Grabar Law Office is Investigating Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire
News headline image
URGENT AARDVARK DEADLINE: Bragar Eagel & Squire, P.C. Urges Aardvark Therapeutics, Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 13th
From Bragar Eagel & Squire
Via GlobeNewswire

Frequently Asked Questions

Is Aardvark Therapeutics, Inc. - Common Stock publicly traded?
Yes, Aardvark Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Aardvark Therapeutics, Inc. - Common Stock trade on?
Aardvark Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Aardvark Therapeutics, Inc. - Common Stock?
The ticker symbol for Aardvark Therapeutics, Inc. - Common Stock is AARD on the Nasdaq Stock Market
What is the current price of Aardvark Therapeutics, Inc. - Common Stock?
The current price of Aardvark Therapeutics, Inc. - Common Stock is 1.250
When was Aardvark Therapeutics, Inc. - Common Stock last traded?
The last trade of Aardvark Therapeutics, Inc. - Common Stock was at 11/03/26 11:48 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.